Retrospective Analysis of Patients with Synchronous Primary Breast and Thyroid Carcinoma by Arer, Ilker Murat et al.
Original Article 
Introduction
Breast cancer is the most common cancer in women and it is the second most common cause of death among women due to cancer (1, 2). 
However, thyroid cancer is projected to be higher than lung, colorectal, and ovarian cancers in near future and estimated to be the third 
most common cancer of women in USA; it has not been a common cause of death due to cancer (3). 5-year survival rate of thyroid cancer 
ranges between 95-97% and 5-year survival rate of women with breast cancer is reported 81.9% therefore breast cancer is the determinant 
for survival in a patient with both breast and thyroid cancer (4, 5).
Both breast and thyroid cancers are frequent among women than men and they both have peak incidence in postmenopausal period (2). 
This finding, may be coincidence, has lead authors to investigate the association between breast and thyroid cancers. It is believed that they 
both have some interactions in hormonal and genetic level (6). Increased risk for second primary malignancies after diagnosis of thyroid 
carcinoma such as salivary gland, small intestine and adrenal gland has been found and this risk increases for breast cancer as the dura-
tion of the follow-up is prolonged (7). Although genetic factors, hormones and irradiation have been regarded as risk factors, no absolute 
relationship has been established yet between them. Either in breast cancer survivors, especially when HER-2 receptor was positive, or 
in thyroid cancer survivors, increased risk of the other cancer has been found (7, 8). This topic has been investigated by cohort and case-
control studies in survivors butfew studies presented patients diagnosed synchronously and treated at the same time (9, 10).
In this study, we present patients who were diagnosed preoperatively as synchronous breast cancer and thyroid pathology and underwent 
mastectomy and thyroidectomy at the same session.
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ABSTRACT
Objective: Breast and thyroid cancers are commonly encountered malignancies. Increased risk of breast cancer in follow-up period of thyroid 
cancer or vice versa has been reported. However, they have some associations, synchronous presentation of these tumors is rare. We presented 12 
patients diagnosed as breast and thyroid cancer and treated at the same time.
Materials and Methods: Mastectomy and thyroidectomy were performed in 19 patients at the same time. 7 patients were excluded because of 
benign thyroid pathology. Therefore 12 patients who had diagnosis of synchronous breast and thyroid cancer were included. Data regarding clinical, 
pathological, treatment and prognostic factors was retrospectively analyzed.
Results: Total thyroidectomy was performed in all patients. The mean age of patients was 54 years (min. 44- max. 70). Only one patient was male. 
Thyroid pathology was detected preoperatively by FDG PET-CT scan in 11 patients. Breast reconstruction was performed in three patients. The 
most commonly seen thyroid malignancy was papillary thyroid carcinoma. Postoperative complication rate was 33.3%. Adjuvant chemotherapy was 
given in 11 patients whereas one patient received adjuvant radiotherapy.
Conclusion: Although synchronous presentation of breast and thyroid cancer is rare, surgical treatment of both of these tumors can be safely per-
formed at the same time. Association of these tumors should be evaluated by large scaled studies.
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Materials and Methods
In total, 1297 thyroidectomies and 1210 mastectomies were per-
formed between November 2011 and January 2016 at our institute. 
Data of patients were retrospectively collected via patient records. 
Among these patients, both mastectomy and thyroidectomy were per-
formed in 19 patients. A total of 729 patients with diagnosis of thyroid 
cancer and 579 patients with diagnosis of breast cancer were found. 
12 patients had diagnosis of synchronous breast and thyroid cancer, 
whereas 7 patients had breast cancer and benign thyroid disease. 
Characteristics of patients, pathological characteristics of both cancers, 
neoadjuvant or adjuvant chemoradiotherapy status, postoperative ra-
dioiodine ablation therapy status, postoperative complications, recur-
rence, survival, disease-free survival and follow-up of the patients are 
given in Table 1 and 2. This study was conducted in accordance with 
the ethical standards of the responsible committee on human experi-
mentation (institutional or regional) and with the Helsinki Declara-
tion.
Statistical Packages for the Social Sciences (SPSS) software package 
was used for statistical analysis version 17.0 (SPSS Inc., Chicago, IL, 
USA). If continuous variables were normal, they were described as the 
mean±standard deviation (p>0.05 in Kolmogorov-Smirnov test or 
Shapira-Wilk (n<30)), and if the continuous variables were not nor-
mal, they were described as the median.
Results
A total of 12 mastectomies and thyroidectomies were performed si-
multaneouly in patients with preoperative diagnosis of breast cancer 
and thyroid pathology. Mean age of patients was 54 years (min. 44- 
max. 70). Only 1 (8.3%) patient was male. Half of the patients had 
preoperative thyroid fine needle aspiration with diagnosis of 3 ma-
lignant cytology, 2 Hurthle cell neoplasia and 1 follicular neoplasia. 
Other 6 patients had either hyperthyroidism or thyroid nodule larger 
than 3 cm. on physical examination and ultrasound. 
11 (91.7%) patients had preoperative FDG PET-CT scan and thyroid 
pathology was detected in all of them. In all 12 patients, primary com-
plaint of the patient was lump or swelling in the breast therefore none 
of the patients presented with primary thyroid pathology. Thyroid 
patholgy was detected on FDG PET-CT scan or physical examination. 
Total thyroidectomy was performed in all patients. Only 1 (8.3%) pa-
tient had papillary thyroid lymph node metastasis in the follow-up 
period and modified radical lymph node dissection was performed. 
(Table 3) shows the details of breast surgeries performed in all cases. 
Immediate breast reconstruction type was silicone implantation and 
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Table 1. Characteristics of patients according to breast pathology 
Patient        Neoadjuvant Adjuvant 
no. Age Sex Operation BC histology BC TNM# ER/PR** therapy  therapy
1 53 F SM+ALND+TT Invasive DC+DCIS T2N1M0 60-70/5 None AC+DT+Tamoxifen 
        RT (66Gy)
2 50 F MRM+IBR+TT Invasive LC+DCIS T2N2M0 60-70/60-70 None AC+DT+TZM  
        RT(50Gy)
3 49 F SM+SLND+IBR+TT Invasive DC+DCIS  T1cN0M0 Neg/Neg None Unknown  
        regimen*
4 48 F MRM+TT Invasive BC TXN2M0/T0N0M0 95/70 AC+DT+TZM TZM RT (50Gy) 
5 44 F SM+SLND+TT Invasive DC+DCIS T1cN0M0 85/95 None AC+Tamoxifen
6 63 F MRM+TT Invasive DC+DCIS T2N1aM0 Neg/Neg None AC+TZM+ 
        Tamoxifen 
7 53 M SiM+SLND+TT Invasive DC+DCIS T1cN0M0 90-95/30-40 None Unknown  
        regimen*
8 50 F MRM+TT Mixed carcinoma+DCIS T2N3aM0 100/70 None AC+DT RT(50Gy)
9 53 F SM+SLND+TT Invasive DC T2N1M0 Neg/Neg None CEF+DT  
        RT(50.4Gy)
10 70 F MRM+TT Invasive DC+DCIS T2N2aM0 90-95/15-20 None CEF+DT RT  
        (50.4Gy)
11 62 F SM+SLND+TT Invasive DC+DCIS T1cN0M0 90-95/10-15 None RT (50.4Gy)
12 53 F MRM+DBRi+TT Invasive DC+DCIS T2N3M0 Neg/Neg None CEF+DT+TZM 
        RT(50Gy)
*: Adjuvant chemoradiotherapy given in another hospital. 
**: Estrogen or progesteron receptor percentage. 
#: Preoperative clinical and postoperative pathological TNM stage (Clinical TNM stage before neoadjuvant therapy and postoperative pathological TNM 
stage was both given for patient number 4) 
AC: adriamycin+cyclophosphamide; ALND: axillary lymph node dissection; BC: breast cancer; CEF: Cyclophosphamide+Epirubicin+Flourouracil; DBRi: 
delayed breast reconstruction with implantation; DC: ductal carcinoma; DCIS: ductal carcinoma insitu; DT: docetaxel; ER: estrogen receptor; F: female; 
IBR: immediate breast reconstruction; LC: lobular carcinoma; M: male, MRM: modified radical mastectomy; PR: progesterone receptor; SM: simple 
mastectomy; SLND: sentinel lymph node dissection; SM: segmental mastectomy; RT: radiotherapy; TT: total thyroidectomy; TZM: trastuzumab
delayed breast reconstruction type was tissue expander and silicone 
implant. 
Only 1 (8.3%) patient who underwent simple mastectomy (SM) with 
axillary lymph node dissection (LND) had positive surgical margins 
and reoperation with wide surgical resection was performed for this 
patient. 
Histopathological findings 
8 (66.8%) invasive ductal breast carcinoma + ductal carcinoma in situ 
and papillary thyroid carcinoma, 1 (8.3%) invasive lobular breast car-
cinoma + ductal carcinoma in situ and papillary thyroid carcinoma, 
1 (8.3%) invasive breast carcinoma and papillary thyroid carcinoma, 
1 (8.3%) mixed (invasive ductal and invasive mucinous) breast car-
cinoma + ductal carcinoma in situ and papillary thyroid carcinoma 
and 1 (8.3%) invasive ductal breast carcinoma and follicular thyroid 
carcinoma. 
Treatment details 
8 (66.8%) patients received adjuvant chemotherapy and radiotherapy, 
1 (8.3%) patient received neoadjuvant and adjuvant chemotherapy 
and radiotherapy, 2 (16.6%) patients received adjuvant chemotherapy 
only and 1 (8.3%) patient received radiotherapy only. Only half of the 
patients (50%) received radioiodine ablation therapy.
Postoperative complications 
Postoperative complications were due to mastectomy. The overall 
complication rate was 16.7%. These complications were seroma in 1 
patient and wound infection in 1 patient, who were treated by con-
servative management. Average disease-free survival was 15.4 months 
(range between 4-30 months). Mean follow-up was 15.6 months 
(range between 4-32 months). No mortality was observed in the fol-
low-up period.
Discussion and Conclusion
Breast cancer is the most common malignancy in women around the 
world. The 5-year relative survival rate of this cancer improved recently 
due to early detection and advances in treatment (11). As survival rates 
and incidence of this cancer has increased, the number of breast can-
cer survivors has also increased. During the diagnosis of breast cancer 
patients, detection of second primary malignancy is a significant issue. 
Warren et al. (12) described synchronous primary cancers as a tumor 
diagnosed simultaneously with breast cancer or within a time interval 
of 6 months. The most common synchronous malignancy of breast 
cancer is thyroid cancer or vise versa (9, 13). There is an increased risk 
of secondary malignancy for breast or thyroid cancer survivors (14). 
Many studies have suggested that there is an association between thy-
roid diseases and breast carcinoma (15) whereas some authors did not 
find any obvious association (16).82
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Table 2. Characteristics of patients according to thyroid cancer, survival and complications 
Patient       Disease free Follow-up Postoperative 
no. Age Sex TC histology TC size (mm) RIA (mci)  survival (Months)  (Months) Complication
1 53 F PC 20 150 29 32 Re-exicision (Breast)
2 50 F PC 15 None 22 22 SSI
3 49 F PC 6 UR 12 12 None
4 48 F PC 8 None 22 22 None
5 44 F PC 17 100 14 14 None
6 63 F PC 7 None 30 30 None
7 53 M PC 6 UR 9 9 None
8 50 F PC 2 None 12 12 Seroma
9 53 F FC 20 100 8 8 None
10 70 F PC 2 None 8 8 None
11 62 F PC 1 None 4 4 None
12 53 F PC 30 100 15 15 None
FC: follicular carcinoma; F: female, M: male; PC: papillary carcinoma; RIA: radioactive iodine ablation; SSI: surgical site infection; TC: thyroid cancer; UR: 
unknown regimen
Table 3. Breast surgery type which was performed 
for patients 
Surgery type Number of patients
MRM  4
SM+sLND 4
SM+aLND 1
SM+aLND+IBR 1
Simple mastectomy+sLND 1
MRM+IBR 1
MRM+DBR 1
aLND: axillary lymph node dissection; DBR: delayed breast 
reconstruction; IBR: immediate breast reconstruction; MRM: modified 
radical mastectomy; sLND: sentinel lymph node dissection; SM: 
segmental mastectomy
The interactions between thyroid and breast disorders are based on 
hormonal and cellular receptor mechanisms (17, 18). In a recent pro-
spective study, although no statistical difference was observed, thyro-
globuline gene polymorphism and autoimmune thyroid disease was 
found to have high prevelance among breast cancer patients (19). Thy-
roid cancer survivors also have been found to develop breast cancer 
early, have more estrogen and progesterone receptor positive tumors, 
and have a greater incidence of mixed invasive cancer (20). Estrogen 
receptors have been found in thyroid tissue (21). Estrogen was found 
to have an influence on thyroid glands (22). The histology of the breast 
cancer that develops after thyroid cancer is different than the general 
population, with a greater percentage of mixed ductal and lobular in-
vasive cancer and a greater percentage of ER/PR-positive tumors (20). 
In this current study, we found high percentage of ER/PR positive 
tumors (66.6%). Although indicated by many studies, an association 
between breast and thyroid cancer still remains controversial. All these 
studies suggest a possible interaction among breast and thyroid can-
cers. 
The first malignancy diagnosed in our patients was breast cancer. Thy-
roid pathology was diagnosed either on physical examination or pre-
operative evaluation of breast cancer with FDG PET-CT scan. FDG 
PET-CT scan has been widely used for the diagnosis, initial staging, 
restaging, early treatment response assessment and evaluation of meta-
static disease response of breast cancer (23). Although it has some dis-
advantages like irradiation, it is useful for detecting metastasis of breast 
cancer. It is reported to have a negative predictive value of 90 % for 
detection of thyroid nodules (24). It also detected 91.7 % of patients 
with thyroid pathology in our study. 
Thyroid hormones have been found to stimulate cell proliferation in 
breast tissue, enhance the estradiol-mediated effects on cell prolifera-
tion, promote growth and induce the expression of progesterone re-
ceptors by mimicing the effects of estradiol (25, 26). Thyroid receptors 
found to be located in both normal and malignant breast cells (27). 
In a recent study, high free T4 levels and thyroid peroxidase antibody 
(TPO-Ab) levels were found to be associated with an increased risk of 
breast cancer (28). In a meta-analysis including 8 cross-sectional stud-
ies, authors found serum levels of free T3, TPO-Ab and thyroglobu-
lin antibody to be significantly higher in patients with breast cancer 
than in healthy controls (29). Therefore, there is great evidence that 
the breast and thyroid tissue has some interactions on hormonal basis 
mainly influenced by the hormones secreted from thyroid gland. Thy-
roid receptors (TR) are encoded by two genes, TRα and TRβ, which 
are located on human chromosomes 17 and 3, respectively. In a recent 
study performed among Chinese people, aberrant expression and mu-
tations of the TRβ1 gene were found to be associated with the devel-
opment of breast cancer (30). Thus, thyroid hormone receptors play a 
role in breast cancer development. 
Although the most common thyroid cancer type found to be associ-
ated with breast cancer is papillary thyroid cancer (85.9%), follicular 
cancer (11%) is also found to be increased in frequency (20). In our 
study, papillary thyroid cancer (91.7%) is also found to be the most 
common histologic type together with breast cancer whereas follicular 
cancer incidence was found as 8.3%.
In this current study we performed both mastectomy and thyroidec-
tomy at the same time. Although our study has a limitation with short 
follow-up period, the main determinant of patients with synchronous 
breast and thyroid cancer is the breast cancer because of shorter sur-
vival rates. Performing mastectomy first and then thyroidectomy in the 
follow-up period may result in delay of the chemotherapy and radio-
therapy. We believe that these two operations can be safely performed 
simultaneously as thyroidectomy adds only 60 minutes to the overall 
operation time, so it does not increase the risk for peroperative or post-
operative complications due to anesthesia. Adjuvant radiotherapy for 
breast cancer reported to have some influence on thyroid tissue leading 
to hypothyroidism (31). Radiation is also known to increase risk for 
thyroid malignancy. Thus, it is better to diagnose thyroid pathology 
before breast cancer treatment and preoperative assesment of thyroid 
gland in patients diagnosed with breast cancer is crucial. 
These different findings from literature represents one of the limitation 
of our study which was the result of small patient population. Retro-
spective design of this study is another limitation.
Although the exact mechanism of association between breast and thy-
roid cancers still remains unknown, synchronous presentation of these 
tumors can be seen. Thus, preoperative assesment of thyroid gland by 
physical examination is mandatory in patients diagnosed with breast 
cancer and if these patients are clinically negative for thyroid pathology 
radiological evaluation can be performed for them. Treatment for both 
of these cancers can be safely performed at the same time.
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